Old Web
English
Sign In
Acemap
>
authorDetail
>
Julie M. Vose
Julie M. Vose
Memorial Sloan Kettering Cancer Center
Tositumomab
Lymphoma
Medicine
Ibritumomab tiuxetan
Refractory
3
Papers
1096
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas
2005
Journal of Clinical Oncology
Richard I. Fisher
Mark S. Kaminski
Richard L. Wahl
Susan J. Knox
Andrew D. Zelenetz
Julie M. Vose
John P. Leonard
Stewart Kroll
Stanley J. Goldsmith
Morton Coleman
Show All
Source
Cite
Save
Citations (219)
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
2001
Journal of Clinical Oncology
Mark S. Kaminski
Andrew D. Zelenetz
Oliver W. Press
Mansoor N. Saleh
John E. Leonard
Louis Fehrenbacher
T. Andrew Lister
Robert J. Stagg
George Tidmarsh
Stew Kroll
Richard L. Wahl
Susan J. Knox
Julie M. Vose
Show All
Source
Cite
Save
Citations (544)
Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
2000
Journal of Clinical Oncology
Julie M. Vose
Richard L. Wahl
Mansoor N. Saleh
Ama Z. Rohatiner
Susan J. Knox
John Radford
Andrew D. Zelenetz
George Tidmarsh
Robert J. Stagg
Mark S. Kaminski
Show All
Source
Cite
Save
Citations (333)
1